FP7 Grant

    The TRAUMAKINE consortium has received a grant from the 7th Framework Programme for Research and Technological Development of the Cooperation Work Programme: Health-2012.

    The Call for Proposal was HEALTH.2012.2.4.4-1: Preclinical and/or clinical development of substances with a clear potential as orphan drugs. FP7-HEALTH-2012-INNOVATION-1.

    This call was designed to support preclinical studies (pharmacological, pharmacodynamics, pharmacokinetics and toxicological) in models and/or clinical studies (including phase III clinical trials) of EU designated orphan medicinal products. The involvement of industry, in particular SMEs, was strongly recommended and the orphan medicinal product needed to be granted the EU orphan designation at the latest on the date of the call closure.

    It was expected that:

    • Project should deliver appropriate information to improve care of rare diseases patients and that the collected data should be of sufficient quality to be further exploited in marketing authorisation requests.
    • The project has appropriate plans to engage with relevant stakeholders such as patient organisations and the European Medicines Agency.
    • Projects would contribute towards the goals of the International Rare Diseases Research Consortium (IRDiRC) that include the development of 200 new therapies for rare diseases by 2020.

     

    FP7_logo.jpgEU_logo.png